Please select the option that best describes you:
Topics:
Genitourinary Cancers • Prostate Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Johns Hopkins • NCI-CCC GU Tumor Board Question
How would you manage asymptomatic radiographic progression from M0 CRPC to M1 CRPC to bone?
PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to radiation.
Answer from: Medical Oncologist at Academic Institution
This is a relatively common scenario presently where the M0-->M1 transition is now occurring during potent AR inhibition in the nmCRPC setting. In general, I manage patients similarly to mCRPC patients progressing on an AR inhibitor and consider factors such as 1) pace of disease and symptoms, 2)...
Sign in or Register to read more